The United Kingdom and the United States have finalized a significant commercial pact that will guarantee zero import taxes on British pharmaceutical products going into the US market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has agreed to raise spending on pharmaceuticals through the public health system. This pledge ensures that tariffs on these vital goods will be held at nothing for a timeframe of the next three years.
This deal is in response to previous warnings to significantly raise duties on branded pharmaceutical imports, with figures discussed as high as 100%.
"This arrangement with the Britain strengthens the international landscape for innovative medicines and brings long-overdue fairness to American-British medicine commerce," a release noted.
Commercial Importance
Medicines are one of the Britain's largest exports to the America, which is easily the biggest market for large British pharmaceutical firms.
Trade data reveal that in the one-year period leading up to September, the UK exported pharmaceutical products totaling billions to the US. This figure represented a significant portion of total UK exports in that timeframe.
"This deal safeguards employment, increases funding and paves the way for the UK to become a international leader for medical research," the Business and Trade Secretary stated.
Specific NHS Changes
The pact involves several key changes from the British government:
- Price Threshold Increase: The UK will raise the price threshold at which it considers new therapies to be too expensive by twenty-five percent.
- Boosted Medicine Funding: There is a target to raise overall public funding on treatments from 0.3% of Gross Domestic Product to 0.6% over the next decade.
- Refund Ceiling: The amount drug companies must return to the NHS to prevent overspending will be restricted at 15%. In the past, refunds topped twenty percent.
Industry Background
The deal comes amid a long-running dispute between the drug companies and the ministers over drug pricing and regulatory access.
This friction were exacerbated by claims that American consumers were paying several times more for the same drugs than consumers in the UK and Europe.
Over the last 18 months, several major pharmaceutical investments in the UK have been paused or cancelled, while major investments have been pledged toward projects in the United States.
One official stated that the NHS needed to increase expenditure on drugs, noting that its budget allocation on drugs had declined as a share of its overall budget over the past decade.
